Hal Wolf named new president, CEO of HIMSS

The Healthcare Information and Management Systems Society (HIMSS) has selected Harold “Hal” Wolf III, an alum of the Chartis Group and Kaiser Permanente, as its new president and CEO.

Wolf’s most recent title has been director of information and digital health strategy at Chartis. His resume also includes a nine-year stint at Kaiser in several different roles, including chief operating officer of its Permanente Foundation and regional CIO for its Colorado facilities. He’s no stranger to HIMSS members, as he’s served as both an advisor to and member of its board and its vice chair for 2016-17.

“It is a great privilege and honor to be chosen to lead HIMSS, an organization whose purpose is to improve healthcare and care outcomes, Wolf said in a statement. “Across the globe, healthcare is challenged to harness the power of information and technology, to solve for the unique environments of each health system and to support the personalization of care to the individual. In alliance with the growing membership of HIMSS and the expansive capabilities of our organization, our collective task is to enable innovation across the full healthcare ecosystem.”

Wolf will be taking the reins from longtime HIMSS leader Stephen Lieber, who announced last year he would retire from the 65,000-member trade group after a 17-year stint as president and CEO. He’ll stay on through the end of the year, with Wolf starting with HIMSS in September before assuming full leadership duties sometime in December.

“Hal Wolf brings to his new role as president and CEO of HIMSS the powerful combination of broad, deep and relevant knowledge, expertise, experience, energy and accomplishments, along with a deep love of and longstanding commitment to HIMSS. His track record of innovation and success spans premier healthcare delivery organizations, digital strategy groups, media companies, global endeavors and more,” said HIMSS board chair Michael Zaroukian, MD, PhD.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.